Barbara Burtness, MD

Barbara Burtness, MD

Oncology New Haven, CT

Co-Leader Developmental Therapeutics

Office Address

  • 333 Cedar St
    New Haven, CT 06520
    Phone: (203) 737-7636

Barbara Burtness, MD

Oncology New Haven, CT

Co-Leader Developmental Therapeutics

Education & Training

  • Memorial Sloan-Kettering
  • Yale-New Haven HospitalYale-New Haven Hospital
  • Yale-New Haven HospitalYale-New Haven Hospital
  • Stony Brook University School of MedicineStony Brook University School of Medicine
  • Bryn Mawr College

Certifications & Licensure

  • PA State Medical LicensePA State Medical License2005 - 2014
  • CT State Medical LicenseCT State Medical License1993 - 2016
  • American Board of Internal MedicineInternal Medicine
  • American Board of Internal MedicineMedical Oncology

    Awards, Honors, & Recognition

    • Regional Top DoctorCastle Connolly, 2014
    • CMS Meaningful Use Stage 1 CertificationEpicCare Ambulatory EMR, Epic Systems Corporation, 2013

    Clinical Trials

    Publications & Presentations


    Journal Articles

    • Images in Medicine: Cetuximab-associated acneiform rash.  Moss J and B Burtness, N Engl J Med 353:e17.
    • Oxaliplatin induces a delayed immune hemolytic anemia: A case report and review of the literature.  Noronha V, B Burtness, J Murren, TP Duffy., Clin Colorectal Ca 5:283-286
    • Bimodal population or pathologist artifact? Correspondence.  4. Rimm DL, Giltnane JM, Moeder C, Harigopal M, Chung GG, Camp RL, Burtness B, J Clin Oncol; 25:2487-8.

    Books/Book Chapters

    • Novel targets in pancreatic cancer: focus on future paths to therapy.  
      Cohen S and B Burtness.
      Editors: .
    • Clinical use in colorectal cancer of monoclonal antibodies to the epidermal growth factor receptor.  
      Burtness B
      Editors: .
    • HER signaling in pancreatic cancer.  
      Burtness B
      Editors: .


    • EGFR inhibition in head and neck cancer – more insights but more questions Forastiere AA and BA Burtness., J Clin Oncol 25:2152-5
    • Docetaxel and irinotecan combination chemotherapy in advanced esophageal cancer. Shanbhag S and B Burtness, Eur J Clin Med Oncol
    • A 5 year follow up of an expanded phase II study evaluating adjuvant sequential dose dense doxorubicin, paclitaxel and cyclophosphamide (ATC) for high-risk breast cancer. Abu-Khalaf M, S Windsor, K Ebisu, S Salikooti, G Chung, M DiGiovanna, B Haffty, M Abrams, L Farber, AD Hsu, M Reiss, D Zelterman, B Burtness., Oncology 69:372-383.


    • Setting Up and Running Multicenter Randomized Trials. American Head and Neck Society Annual Meeting, Toronto.
    • Integrating Targeted Therapies into Standard Treatments, Meet the Professor Session. American Head and Neck Society Annual Meeting,Toronto.
    • Esophagogastric Discussion: Trials in Unselected Patients, Gastrointestinal (Non-colorectal) Oral Abstract Session. American Society of Clinical Oncology Annual Meeting, Chicago.

    Hospital Affiliations

    Insurance Accepted

    • Aetna Choice POS II
    • Aetna HMO
    • AmeriHealth Direct POS
    • Amerihealth HMO
    • AmeriHealth PPO
    • BCBS Blue Card PPO
    • CIGNA Open Access
    • First Health PPO
    • Great West PPO
    • Humana ChoiceCare Network PPO
    • IBC Keystone HMO / POS
    • IBC Personal Choice PPO
    • Multiplan PHCS PPO
    • Multiplan PPO
    • Oxford Health Freedom
    • Oxford Health Liberty
    • QualCare HMO
    • QualCare PPO
    • United Healthcare - Direct Choice Plus POS
    • United Healthcare - Direct Options PPO
    • The full profile is locked and available to verified physicians only.
      Join over 60% of U.S. physicians already on Doximity and get access to this and over 700,000 physician CVs. Find your physician profile

    Physicians, view Dr. Burtness's full Doximity profile to:

    • Trade HIPAA-secure messages
    • Send and receive online faxes
    • Refer a patient
    • See their complete CV